Global Point of Care
Home > Products

ID NOW™ COVID-19

Molecular. In minutes. On the front line.

ID NOW™ is a leading molecular point-of-care platform in the United States, trusted by hospitals, physician offices, and urgent care clinics nationwide.

The ID NOW™ COVID-19 assay is now available for use on the ID NOW platform under U.S. Food and Drug Administration Emergency Use Authorization (EUA). The ID NOW™ COVID-19 rapid test delivers high-quality molecular positive results in as little as 5 minutes, targeting the coronavirus (COVID-19) RdRp Gene.

Timely results enable healthcare professionals to make appropriate and more efficient treatment and infection control decisions. EUA supports flexible near patient testing environments.

Only available in the US.

ID NOW™ COVID-19
ID Now COVID-19 2.0 Assay will
be available soon

Stay informed. Sign up to receive updates.

Sign up
Benefits
  • Positive results may be detected in as little as 5 minutes 
  • Negative results in 13 minutes
  • Molecular technology targeting COVID-19 RdRp gene
  • Designed for near patient testing in a variety of healthcare environments1
  • Room temperature storage
  • Direct sample types include: Nasal, Throat, and Nasopharyngeal swabs
  • Facilitates effective patient management
Webinar

Watch the replay for multi-disciplinary updates on variant surveillance and testing protocols from Europe to the U.S., and explore COVID-19 testing protocols to optimize patient care and public health readiness with an uncertain upcoming influenza season.

Watch Now
One Abbott solution for patient testing, result capture and data reporting

A simple, reliable and secure connectivity and reporting solution, offering ID NOW COVID-19 test reporting within 24 hours for decentralized environments to help you manage data for CARES Act requirements without infrastructure burden.

One Abbott Solution
Helpful Documents
  • Small footprint enables ease of use at point of care
  • Actionable results in 13 minutes or less
  • Direct sample types include: Nasal, Throat, and Nasopharyngeal swabs
  • Simple operation via visual touchscreen
  • Dimensions - 8.15” W x 5.71” H x 7.64” D (207 mm W x 145 mm H x 194 mm D)
  • Assay kit contains all necessary components for testing to include: 24 tests, swabs for sample collection, pipettes, positive and negative controls
ID NOW™ System
 Code
ID NOW™ Instrument
 NAT-000 (Global)
ID NOW™ COVID-19 24 Test Kit 190-000 (US)
ID NOW™ COVID-19 Control Kit (12 pos, 12 neg) 190-080 (US)
ID NOW™ Barcode Scanner OPR2001ZWU1-201 (Global)
Abbott Barcode Scanner L22XWU1200 (US)
Universal Printer 55115 (Global)
  IDNOWPRINT, formerly alereiprinter (US)
Related Products
ID NOW™
ID NOW™
ID NOW™ Influenza A & B 2
ID NOW™ Influenza A & B 2
ID NOW™ RSV
ID NOW™ RSV
Alere™ i Strep A 2
ID NOW™ STREP A 2

ID NOW™ COVID-19 and ID NOW COVID-19 2.0 have not been FDA cleared or approved. They have been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

1. Please see ID NOW Instrument User manual for additional operating environment requirements.

Stay informed

Sign up to receive valuable updates from Abbott.